C4 Therapeutics, Inc. Logo

C4 Therapeutics, Inc.

Developing protein degrader medicines to treat cancer and other serious diseases.

CCCC | NDAQ

Overview

Corporate Details

ISIN(s):
US12529R1077
LEI:
Country:
United States of America
Address:
490 ARSENAL WAY, 2472 WATERTOWN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

C4 Therapeutics, Inc. (C4T) is a clinical-stage biopharmaceutical company focused on developing a new class of medicines through targeted protein degradation (TPD). The company's approach utilizes the body's natural protein disposal mechanisms to selectively eliminate disease-causing proteins. C4T leverages its proprietary TORPEDO® (Target Oriented Protein Degrader Optimizer) platform to design and advance a pipeline of small-molecule drug candidates aimed at treating cancer and other serious diseases. Its portfolio includes clinical programs such as Cemsidomide (CFT7455), CFT8919, and CFT1946.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all C4 Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for C4 Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for C4 Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea 034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan 4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America CTXR
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea 311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea 063160
Clearmind Medicine Inc. Logo
Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.
United States of America CMND

Talk to a Data Expert

Have a question? We'll get back to you promptly.